TNFRSF10B and neuroblastoma: LY303511 upregulated DR4 and DR5 by activation of JNK and ERK pathways and enhanced TRAIL induced apoptosis in neuroblastoma cells, and the induction of DRs and TRAIL induced apoptosis were reduced by treatment of JNK and ERK inhibitors[25].